ClinicalTrials.gg
TerminatedNCT04372121EDELWEISS 5Updated Apr 2, 2025Results posted

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

A Phase 3 interventional study of 75 mg linzagolix tablet and 200 mg linzagolix tablet in Endometriosis, sponsored by Kissei Pharmaceutical Co., Ltd.. Terminated at 25 sites in 3 countries. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Why this study was terminated
This study is an extension of Study 18-OBE2109-002 that has been terminated due to enrolment challenges. Consequently, this study has also been terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.

Started
2020
with 1 other
Phase 3
5 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
9 of 10
Kissei Pharmaceutical Co., Ltd.

Among the 10 studies testing linzagolix in Endometriosis, this one is one of 2 that started in 2020, is one of 5 in phase 3, and was the 9th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →

About linzagolix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing linzagolix in Endometriosis as a file.
02

Study summary

The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have already completed 6 months of linzagolix treatment at a dose of 75 mg alone or of 200 mg in combination with ABT (E2 1 mg / NETA 0.5 mg), in the management of moderate to severe endometriosis-associated pain (EAP) in women with surgically confirmed endometriosis.

Read the detailed description

This is a prospective, randomized, double-blind study. Subjects who have completed the 6-month Treatment Period in 18-OBE2109-002 - Edelweiss 2 study (herein referred to as main study) will be invited to enter the present extension study. Month 6 visit of the main study is a decision point for Subjects to either end treatment and enter a post-treatment follow up (part of the main study), or to opt for a 6-month treatment extension. All subjects will receive once daily either linzagolix 75 mg alone (with ABT placebo) or 200 mg combined with ABT for 6 months. Subjects who received placebo during the main study will be randomized to either linzagolix 75 mg alone (with ABT placebo) or linzagolix 200 mg with ABT. Subjects who received active treatment during the main study will continue with the same treatment. Double-dummy design will be used in order to maintain the blinding of the study.

After end of treatment in the extension study (6-month treatment period: from Month 6 to Month 12), subjects will enter a post-treatment Follow-Up Period of 6 months with no investigational medicinal product (IMP) or - for subjects willing to continue treatment - a second extension study will be proposed.

03

Conditions studied

  • Endometriosis

Keywords

  • Dysmenorrhea
  • Dyspareunia
  • Dyschezia
  • Non-menstrual pelvic pain
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subject must have:

  • completed the 6-month treatment in the main study
  • agreed to continue to use only the analgesic rescue medication permitted by the protocol during the Treatment and Follow-up Periods
  • agreed to continue to comply with the requirements of the study protocol for the duration of the extension study

Exclusion criteria

Exclusion Criteria:

The subject will be excluded if she:

  • is pregnant or breast feeding or is planning a pregnancy within the duration of the of the study (including the Follow-up Period)
  • likely to require treatment during the study with any of the restricted medications
  • has any other gynecologic condition identified during the main study on transvaginal ultrasound (TVUS), on endometrial or at the manual breast examination, which might interfere with the study efficacy and safety objectives
  • meets any of the main study discontinuation criteria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Linzagolix 75 mg

    Drug: 75 mg linzagolix tablet · Drug: Placebo tablet to match 200 mg linzagolix tablet · Drug: Placebo capsule to match Add-back capsule

  • Experimental
    Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)

    Drug: 200 mg linzagolix tablet · Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg) · Drug: Placebo tablet to match 75 mg linzagolix tablet

Interventions

  • For oral administration once daily

  • For oral administration once daily

  • DrugAdd-back capsule (E2 1 mg / NETA 0.5 mg)

    Drug page: Estradiol

    For oral administration once daily

  • DrugPlacebo tablet to match 75 mg linzagolix tablet

    For oral administration once daily

  • DrugPlacebo tablet to match 200 mg linzagolix tablet

    For oral administration once daily

  • DrugPlacebo capsule to match Add-back capsule

    For oral administration once daily

06

What researchers measure

Primary outcomes

  1. Dysmenorrhea

    Monthly Severity Data of dysmenorrhea (DYS) at Month 6 were measured on a 4-point (0: No pain, 1: Mild pain, 2: Moderate pain, 3: Severe pain) Verbal Rating Scale (VRS). The "Mean±SD" of Monthly Severity Data for each treatment arm were calculated and provided as the efficacy data.

    Time frame: 6 Months

  2. Non-menstrual Pelvic Pain

    Monthly Severity Data of non-menstrual pelvic pain (NMPP) at Month 6 were measured on a 4-point (0: No pain, 1: Mild pain, 2: Moderate pain, 3: Severe pain) Verbal Rating Scale (VRS). The "Mean±SD" of Monthly Severity Data for each treatment arm were calculated and provided as the efficacy data.

    Time frame: 6 Months

07

Results

Posted Mar 19, 2025
Limitations and caveats
The main study (NCT03986944) was prematurely terminated by the impact of the COVID-19 pandemic. As a result, the extension study (NCT04372121) was also terminated early before enough subjects could be enrolled and treated for the evaluation of the planned efficacy endpoints. So, we quantified the Monthly Severity Data at Month 6 for the 5 subjects (i.e. 0: No pain, 1: Mild pain, 2: Moderate pain, 3: Severe pain) and showed the "Mean±SD" for each treatment arm as the efficacy data.

Participant flow

Of the 85 subjects randomized in the Edelweiss 2 study, 37 completed the 6-month treatment. Of the 37 subjects, 30 subjects opted to participate in the current extension study (7 from Placebo, 13 from LGX 75 mg, and 10 from LGX 200 mg+ABT). At entry into the extension study, the 7 subjects in the placebo group were re-randomized to an active LGX group (PBO/LGX 75 mg: 3, PBO/LGX 200 mg+ABT: 4). Subjects receiving LGX during Edelweiss 2 study, continued treatment as randomized in the main study.

Participant flow — Overall Study
MilestoneLGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABT
Started131034
Completed3412
Not completed10622
Withdrew: Lost to follow-up0001
Withdrew: Protocol violation0010
Withdrew: Withdrawal by subject3100
Withdrew: Study termination6511
Withdrew: Hysterectomy planned1000

Outcome measures

PrimaryDysmenorrhea

Monthly Severity Data of dysmenorrhea (DYS) at Month 6 were measured on a 4-point (0: No pain, 1: Mild pain, 2: Moderate pain, 3: Severe pain) Verbal Rating Scale (VRS). The "Mean±SD" of Monthly Severity Data for each treatment arm were calculated and provided as the efficacy data.

Time frame:
6 Months
Reported as:
Mean · score on a scale
Dysmenorrhea
score on a scaleLGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABT
Dysmenorrhea2.0 ± 0.02.0 ± 0.02.5 ± 0.52.0 ± 0.0
PrimaryNon-menstrual Pelvic Pain

Monthly Severity Data of non-menstrual pelvic pain (NMPP) at Month 6 were measured on a 4-point (0: No pain, 1: Mild pain, 2: Moderate pain, 3: Severe pain) Verbal Rating Scale (VRS). The "Mean±SD" of Monthly Severity Data for each treatment arm were calculated and provided as the efficacy data.

Time frame:
6 Months
Reported as:
Mean · score on a scale
Non-menstrual Pelvic Pain
score on a scaleLGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABT
Non-menstrual Pelvic Pain1.0 ± 0.02.0 ± 0.02.5 ± 0.52.0 ± 0.0

Adverse events

Collected over Month 6 to Month 12 of the treatment period. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LGX 75 mg0/13 (0%)1/13 (7.7%)4/13 (30.8%)
LGX 200 mg+ABT0/10 (0%)0/10 (0%)4/10 (40%)
Placebo/LGX 75 mg0/3 (0%)0/3 (0%)0/3 (0%)
Placebo/LGX 200 mg+ABT0/4 (0%)0/4 (0%)0/4 (0%)
Most frequent serious events
Most frequent serious events
EventLGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABT
Gallbladder polypHepatobiliary disorders1/130/100/30/4
Most frequent other events
Most frequent other events
EventLGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABT
COVID-19Infections and infestations0/132/100/30/4
Menstruation irregularReproductive system and breast disorders0/131/100/30/4
Vaginal dischargeReproductive system and breast disorders0/131/100/30/4
Urinary tract infectionInfections and infestations1/130/100/30/4
Pelvic painReproductive system and breast disorders1/130/100/30/4
Tendon injuryInjury, poisoning and procedural complications1/130/100/30/4
Platelet count decreasedInvestigations1/130/100/30/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
<=18 years00000
Between 18 and 65 years13103430
>=65 years00000
Age, Continuous
Age, Continuous(Years)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Mean33.6 ± 6.030.6 ± 7.729.0 ± 7.231.5 ± 7.131.9 ± 6.7
Age, Customized
Age, Customized(Years)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Median34.0 (29.0 to 36.0)30.5 (27.0 to 35.0)31.0 (21.0 to 35.0)33.5 (26.0 to 37.0)32.0 (28.0 to 36.0)
Sex: Female, Male
Sex: Female, Male(Participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Female13103430
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Hispanic or Latino351110
Not Hispanic or Latino1052320
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American11002
White1293428
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Canada01001
Puerto Rico21003
United States1183426
Weight
Weight(kg)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Mean80.992 ± 14.42576.446 ± 22.39872.910 ± 29.70176.143 ± 27.30077.979 ± 18.972

1 further baseline measures are reported on the registry.

08

Study locations

25 sites
  • Applied Res Center of Ar / Id # 735
    Little Rock, Arkansas 72212, United States
  • Futura Research, Inc. / ID # 781
    Norwalk, California 90650, United States
  • Adv Womens Health Institute / ID # 761
    Greenwood Village, Colorado 80111, United States
  • Red Rocks OB/GYN / ID # 732
    Lakewood, Colorado 80228, United States
  • Dr. David I. Lubetkin, LLC / ID # 703
    Boca Raton, Florida 33486, United States
  • Coral Way Research / ID # 799
    Miami, Florida 33135, United States
  • La Salud Research Clinic, Inc. / ID # 824
    Miami, Florida 33155, United States
  • A Premier Medical Research of Florida, LLC / ID # 752
    Orange City, Florida 32763, United States
  • Clinical Associates of Orlando, LLC / ID # 779
    Orlando, Florida 32806, United States
  • Providea Health Partners LLC / ID # 734
    Evergreen Park, Illinois 60805, United States
  • Onyx Clinical Research / ID # 793
    Flint, Michigan 48532, United States
  • Valley OBGYN / ID # 704
    Saginaw, Michigan 48602, United States
  • ClinOhio Res Services, LLC / ID # 722
    Columbus, Ohio 43213, United States
  • Complete Healthcare for Women / ID # 801
    Columbus, Ohio 43213, United States
  • Hilltop OBGYN / ID # 711
    Franklin, Ohio 45005, United States
  • Clinical Research Associates Inc / ID # 802
    Nashville, Tennessee 37203, United States
  • Austin Area ObGyn PLLC / ID # 701
    Austin, Texas 78758, United States
  • OB/GYN North Austin / ID # 764
    Austin, Texas 78758, United States
  • HCWC dba DiscoveryClinical Trials / ID # 771
    Dallas, Texas 75231, United States
  • Signature Gyn Services / ID # 726
    Fort Worth, Texas 76104, United States
  • Medical Colleagues of Texas / ID # 819
    Katy, Texas 77450, United States
  • Maximos OB/GYN
    League City, Texas 77573, United States
  • Physicians Research Options / ID # 766
    Draper, Utah 84020, United States
  • CARe Clinic / ID # 872
    Red Deer, Alberta T4N 6V7, Canada
  • Puerto Rico Medical Res Inc. / ID # 890
    Ponce, 00717, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Jan 2021, 9 months.

Results were first posted in Mar 2025, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2020
First posted
May 1, 2020
StartActual
Mar 23, 2020
Primary completionActual
Jan 8, 2021
CompletionActual
Feb 16, 2021
Results first posted
Mar 19, 2025
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04372121
Responsible party
Sponsor
First posted
May 1, 2020
Start date
Mar 23, 2020
Primary completion
Jan 8, 2021
Completion
Feb 16, 2021
Results posted
Mar 19, 2025
Last update
Apr 2, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion